Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neurofibromatosis 1 2Thrombocythemia, Essential 1Stomatitis 1Stomach Neoplasms 1Radiation Pneumonitis 1Primary Myelofibrosis 1Polycythemia Vera 1Polycystic Ovary Syndrome 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Glioblastoma 1Colorectal Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Breast Neoplasms 1Attention Deficit Disorder with Hyperactivity 1Acute Kidney Injury 1

Interventions

Paclitaxel 69Bevacizumab 62Carboplatin 53pembrolizumab 46olaparib 32Specimen Handling 27Gemcitabine 27Cyclophosphamide 26Magnetic Resonance Spectroscopy 24liposomal doxorubicin 22Cisplatin 21niraparib 20Taxes 18Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 12Fulvestrant 12Disulfides 12Oxaliplatin 10mirvetuximab soravtansine 9durvalumab 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9Blood Specimen Collection 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Acetylcysteine × 1 year × Clear all
NCT04520139 2026-04-29

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

University of California, Irvine

Phase 1/2 Not yet recruiting
102 enrolled
Gynecologic

Chemotherapy-Related Cognitive Impairment, Ovarian Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡